Will the Top at 2.65 USD be tested or will it go down to 2,0 USD (Volume Point of Control) first?
The most analysts aim for 7.5 USD for end of this year. With the cancer therapies in their portfolio it will be there a lot earlier I think.
The most analysts aim for 7.5 USD for end of this year. With the cancer therapies in their portfolio it will be there a lot earlier I think.
